JP2002505672A5 - - Google Patents

Download PDF

Info

Publication number
JP2002505672A5
JP2002505672A5 JP1999503267A JP50326799A JP2002505672A5 JP 2002505672 A5 JP2002505672 A5 JP 2002505672A5 JP 1999503267 A JP1999503267 A JP 1999503267A JP 50326799 A JP50326799 A JP 50326799A JP 2002505672 A5 JP2002505672 A5 JP 2002505672A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1999503267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002505672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/012278 external-priority patent/WO1998056807A1/en
Publication of JP2002505672A publication Critical patent/JP2002505672A/ja
Publication of JP2002505672A5 publication Critical patent/JP2002505672A5/ja
Ceased legal-status Critical Current

Links

JP50326799A 1997-06-13 1998-06-12 水溶液中における保護されていないか又はｎ−末端システインで保護されたペプチドの固相での自然化学連結 Ceased JP2002505672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US60/049,553 1997-06-13
PCT/US1998/012278 WO1998056807A1 (en) 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution

Publications (2)

Publication Number Publication Date
JP2002505672A JP2002505672A (ja) 2002-02-19
JP2002505672A5 true JP2002505672A5 (enExample) 2005-12-22

Family

ID=21960431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50326799A Ceased JP2002505672A (ja) 1997-06-13 1998-06-12 水溶液中における保護されていないか又はｎ−末端システインで保護されたペプチドの固相での自然化学連結

Country Status (9)

Country Link
US (4) US6326468B1 (enExample)
EP (1) EP1001968B1 (enExample)
JP (1) JP2002505672A (enExample)
AT (2) ATE354584T1 (enExample)
AU (1) AU745094B2 (enExample)
CA (1) CA2292724A1 (enExample)
DE (2) DE69828287T2 (enExample)
ES (2) ES2235336T3 (enExample)
WO (1) WO1998056807A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
ES2235336T3 (es) * 1997-06-13 2005-07-01 Gryphon Therapeutics, Inc. Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa.
US6844161B2 (en) 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
CA2372164A1 (en) * 1999-03-11 2000-09-14 Gerd G. Kochendoerfer Chemical synthesis and use of soluble membrane protein receptor domains
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20020155455A1 (en) * 2000-08-11 2002-10-24 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
JP2004507557A (ja) * 2000-09-01 2004-03-11 グリフォン　セラピューティクス，インコーポレーテッド 求核物質に対して安定なチオエステル生成化合物、製造および使用の方法
CA2435394C (en) * 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
JP4408628B2 (ja) * 2001-03-09 2010-02-03 ボストン プローブス，インコーポレイテッド 組み合わせオリゴマーならびにそれらの調製のためのライブラリーに適する、方法、キット、および組成物
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7781488B2 (en) * 2002-06-10 2010-08-24 Amylin Pharmaceuticals, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
JP2005531616A (ja) * 2002-06-29 2005-10-20 アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング イソフラボン濃縮物およびその製造法
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
AU2003300859A1 (en) * 2002-12-11 2004-06-30 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1631597A4 (en) * 2003-05-22 2007-07-11 Gryphon Therapeutics Inc SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
DE602005023714D1 (de) 2004-02-20 2010-11-04 Biosurface Eng Tech Inc Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
EP1757609B1 (en) 2004-04-09 2013-10-16 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
EP1749022A2 (en) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
CN102343084A (zh) 2005-03-31 2012-02-08 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7674881B2 (en) * 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2046350A4 (en) 2006-06-22 2011-09-14 Biosurface Eng Tech Inc COMPOSITION AND METHOD FOR DELIVERING AMPLIFIER / CO-ACTIVATOR OF BMP-2 TO ENHANCE OSTEOGENESIS
EP2120985B1 (en) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 peptides for use in the treatment of psychotic and anxiety disorders
WO2009032133A2 (en) * 2007-08-28 2009-03-12 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
US8927485B2 (en) * 2010-02-18 2015-01-06 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
ES2563091T3 (es) 2010-09-28 2016-03-10 Amylin Pharmaceuticals, Llc Polipéptidos modificados genéticamente que tienen duración de acción potenciada
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
US9498538B2 (en) 2012-05-21 2016-11-22 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
WO2017151939A1 (en) * 2016-03-02 2017-09-08 The Brigham And Women's Hospital, Inc. Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
US11214592B2 (en) * 2017-03-02 2022-01-04 Glytech, Inc. Production method for amino-acid polymer
CA3114571A1 (en) 2018-10-01 2020-04-09 Universite De Geneve Methods for producing a plurality of polypeptide variants suitable for biological analysis
KR102769851B1 (ko) * 2018-11-30 2025-02-20 가부시키가이샤 도우사 고가쿠 겐큐쇼 펩티드 티오에스테르 및 펩티드의 신규 제조 방법
CA3157359A1 (en) 2019-10-10 2021-04-15 1859, Inc. Methods and systems for microfluidic screening
JP7289799B2 (ja) * 2019-10-23 2023-06-12 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 オリゴペプチドリンカー中間体及びその製造方法
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
MX9708500A (es) * 1995-05-04 1998-02-28 Scripps Research Inst Sintesis de proteinas mediante ligacion quimica nativa.
WO1998028434A1 (en) 1996-12-24 1998-07-02 The Scripps Research Institute General chemical ligation
ES2235336T3 (es) * 1997-06-13 2005-07-01 Gryphon Therapeutics, Inc. Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa.
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Similar Documents

Publication Publication Date Title
JP2000509942A5 (enExample)
JP2000507042A5 (enExample)
JP2001513697A5 (enExample)
JP2001523365A5 (enExample)
JP2002503427A5 (enExample)
JP2002503227A5 (enExample)
JP2002510996A5 (enExample)
JP2001509311A5 (enExample)
JP2001515389A5 (enExample)
JP2002500675A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2001511714A5 (enExample)
JP2002505672A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2001508847A5 (enExample)
JP2001524946A5 (enExample)
JP2001511717A5 (enExample)
JP2000510969A5 (enExample)
JP2000508836A5 (enExample)